Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Patients at Risk for Melanoma”

12 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 12 of 12 results

Testing effectiveness (Phase 2)Ended earlyNCT04455503
What this trial is testing

Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1

Who this might be right for
Melanoma Stage IVMelanoma Stage III
Evaxion Biotech A/S 15
Testing effectiveness (Phase 2)Active Not RecruitingNCT02713269
What this trial is testing

Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord

Who this might be right for
Malignant Digestive System NeoplasmMetastatic Head and Neck CarcinomaMetastatic Kidney Carcinoma+10 more
M.D. Anderson Cancer Center 60
Not applicableStudy completedNCT01610531
What this trial is testing

COPARIME: Pilot Study of a Target Detection of Malignant Melanoma

Who this might be right for
Patients at Risk for Melanoma
Nantes University Hospital 4,118
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07492121
What this trial is testing

Screening for Brain Metastases

Who this might be right for
Lung Cancer Stage IVMelanoma Stage IVBreast Cancer Metastatic
University of Zurich 180
Not applicableWithdrawnNCT00378781
What this trial is testing

Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection

Who this might be right for
Cancer
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Study completedNCT01612221
What this trial is testing

Oral N-acetylcysteine for Protection of Human Nevi Against UV-induced Oxidative Stress/Damage in Vivo

Who this might be right for
Patients at Risk for Melanoma
University of Utah 100
Not applicableStudy completedNCT03137511
What this trial is testing

Optimizing Access to Care Through New Technologies: a Randomized Study Evaluating the Impact of Telephone Contact and the Sending by the General Practitioner of Suspicious Lesions Melanoma Photographs Taken With a Smartphone, on the Time Limit to the Consultation With a Dermatologist

Who this might be right for
Patients at Risk for Melanoma
Nantes University Hospital 270
Large-scale testing (Phase 3)Ended earlyNCT04410445
What this trial is testing

Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence

Who this might be right for
MelanomaMelanoma Stage IIIMelanoma Stage IV+1 more
Nektar Therapeutics 765
Testing effectiveness (Phase 2)Study completedNCT00059475
What this trial is testing

Peptide Vaccination for Patients at High Risk for Recurrent Melanoma

Who this might be right for
Melanoma
National Cancer Institute (NCI) 138
Large-scale testing (Phase 3)Study completedNCT01667419
What this trial is testing

Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma

Who this might be right for
Melanoma
Hoffmann-La Roche 498
Not applicableUnknownNCT02907827
What this trial is testing

Whole-body DW-MRI and cfDNA Analysis for the Surveillance of Melanoma Patients at High Risk for Recurrence.

Who this might be right for
Melanoma
Universitair Ziekenhuis Brussel 100
Testing effectiveness (Phase 2)Study completedNCT00462280
What this trial is testing

Lovastatin in Treating Patients At High Risk of Melanoma

Who this might be right for
Precancerous ConditionStage 0 MelanomaStage I Melanoma+1 more
National Cancer Institute (NCI) 80